ZERO Prostate Cancer Webinar_banner

A Town Hall Conversation with ZERO’s Racial Disparities Task Force

Black man with a quote saying black men are more likely to be diagnosed with prostate cancer

Black men are more likely to be diagnosed with prostate cancer and to die from the disease than white men. Recent research suggests that these differences in health outcomes are likely caused by several factors within the U.S. healthcare system including access to care, insurance status, racial biases, and distrust in the medical system – it cannot be solely explained by genetic differences. Our Racial Disparities Task Force Co-Chairs, Robert Ginyard and Dr. Kelvin Moses were joined by ZERO’s Vice President of Health Equity, Dr. Reggie Tucker-Seeley to discuss the progress that has been made since the launch of the Task Force and the road map forward.


Sponsored by

decorative background image


Sharply dressed man in a blue suit with a checkered button up shirt next to a brick wall
Jamie Bearse, Past President

Past President of ZERO Cancer between 2002-2023, Jamie was instrumental as a leader, mentor, advocate, and champion for the families we serve.

Dr. Kelvin Moses
Kelvin Moses, MD, PhD, Member, Board of Directors

Dr. Kelvin A. Moses is an Associate Professor of Urologic Surgery at Vanderbilt University Medical Center, and director of the Comprehensive Prostate Cancer Clinic.

He is a Phi Beta Kappa graduate of Morehouse College, and received his MD and PhD training at Baylor College of Medicine. He completed his urology training at Emory University, followed by a fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center, where he served as Chief Administrative Fellow.

His clinical practice focuses on advanced prostate cancer, including conducting several clinical trials, as well as surgical management of advanced renal and testicular cancer. His work focuses on addressing health disparities in urologic cancers, determining the role of health literacy in patient interactions with the health care system, and optimal care for patients with metastatic and/or castrate-resistant prostate cancer. Dr. Moses also serves on ZERO's Board of Directors and Medical Advisory Board.